Sangamo Therapeutics (SGMOQ) Income from Non-Controlling Interests (2018 - 2021)

Sangamo Therapeutics' Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at -$5000.0 for Q2 2021.

• On a quarterly basis, Income from Non-Controlling Interests rose 86.11% year-over-year to -$5000.0 in Q2 2021; TTM through Mar 2022 was -$5000.0, a 92.96% increase from a year earlier, with the FY2021 full-year figure at -$11000.0, up 91.27% from the prior year.
• Income from Non-Controlling Interests climbed to -$5000.0 in Q2 2021 per SGMOQ's latest filing, from -$6000.0 in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $42000.0 in Q3 2020 and bottomed at -$555000.0 in Q4 2018.
• The 4-year median for Income from Non-Controlling Interests is -$54000.0 (2019), against an average of -$100272.7.
• Biggest YoY gain for Income from Non-Controlling Interests was 123.46% in 2020; the steepest drop was 31.48% in 2020.
• Year by year, Income from Non-Controlling Interests stood at -$555000.0 in 2018, then surged by 90.27% to -$54000.0 in 2019, then sank by 31.48% to -$71000.0 in 2020, then soared by 92.96% to -$5000.0 in 2021.
• Per Business Quant, the three latest SGMOQ Income from Non-Controlling Interests figures stand at -$5000.0 (Q2 2021), -$6000.0 (Q1 2021), and -$71000.0 (Q4 2020).